381 related articles for article (PubMed ID: 19393831)
1. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
2. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
3. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
5. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
6. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes.
Tchaikovski V; Olieslagers S; Böhmer FD; Waltenberger J
Circulation; 2009 Jul; 120(2):150-9. PubMed ID: 19564559
[TBL] [Abstract][Full Text] [Related]
9. How do angiopoietins Tie in with vascular endothelial growth factors?
Saharinen P; Bry M; Alitalo K
Curr Opin Hematol; 2010 May; 17(3):198-205. PubMed ID: 20375888
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
11. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.
Takahashi H; Shibuya M
Clin Sci (Lond); 2005 Sep; 109(3):227-41. PubMed ID: 16104843
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
Casanovas O; Hicklin DJ; Bergers G; Hanahan D
Cancer Cell; 2005 Oct; 8(4):299-309. PubMed ID: 16226705
[TBL] [Abstract][Full Text] [Related]
14. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
16. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
17. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Lohela M; Bry M; Tammela T; Alitalo K
Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
[TBL] [Abstract][Full Text] [Related]
18. VEGF as a target of therapy in gastrointestinal oncology.
Los M; Voest EE; Borel Rinkes IH
Dig Surg; 2005; 22(4):282-93. PubMed ID: 16174985
[TBL] [Abstract][Full Text] [Related]
19. Targeting endothelial and tumor cells with semaphorins.
Bielenberg DR; Klagsbrun M
Cancer Metastasis Rev; 2007 Dec; 26(3-4):421-31. PubMed ID: 17768598
[TBL] [Abstract][Full Text] [Related]
20. VEGF function in vascular pathogenesis.
Ng YS; Krilleke D; Shima DT
Exp Cell Res; 2006 Mar; 312(5):527-37. PubMed ID: 16330026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
